Thera-SAbDab

MEPOLIZUMAB

>   Structural Summary
TherapeuticMepolizumab
TargetIL5
Heavy ChainQVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed1999
INN Year Recommended2000
Companies InvolvedGlaxoSmithKline, McMaster University, National Institute of Allergy and Infectious Diseases
Conditions ApprovedAsthma, Churg-Strauss syndrome
Conditions ActiveChronic obstructive pulmonary disease, Hypereosinophilic syndrome, Nasal polyps, Atopic dermatitis, Eosinophilic oesophagitis
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]